Dynamic neutrophil-to-lymphocyte ratio as an independent prognostic marker of overall survival in patients receiving immune checkpoint inhibitors: a Latin American cohort study
Parag Chatterjee, Belén Insagaray, Tomás Ferraz, Mario González, Gianina Muñoz, Valeria Pombo, Romina Barrios, Mauricio Cuello · 2026
Read Dynamic neutrophil-to-lymphocyte ratio as an independent prognostic marker of overall survival in patients receiving immune checkpoint inhibitors: a Latin American cohort study by Parag Chatterjee, Belén Insagaray, Tomás Ferraz, Mario González, Gianina Muñoz, Valeria Pombo, Romina Barrios, Mauricio Cuello (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13629184.txt.
Description
Parag Chatterjee and co-authors track a blood ratio in cancer patients on immune drugs in a 2026 study. The ratio sets two white cell types against each other and marks body-wide swelling. Most past proof rests on one reading at the start of care.
The team read records of sixty-eight patients with advanced tumors at two centers in Uruguay. Ratio values were taken at the start and at each care cycle, up to twelve. Survival was then charted against both the start value and its shifts over time. Care response at six months and immune side effects were also logged. The work tests repeat readings in a real-world Latin American group.
Catalog record
| CREATOR | Parag Chatterjee, Belén Insagaray, Tomás Ferraz, Mario González, Gianina Muñoz, Valeria Pombo, Romina Barrios, Mauricio Cuello |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |